Publicado Oct 28, 2020



PLUMX
Almetrics
 
Dimensions
 

Google Scholar
 
Search GoogleScholar
Descargas


Suad Siuffi Campo https://orcid.org/0000-0001-5357-0005

Natalia Jiménez Cardozo http://orcid.org/0000-0002-7206-499X

Alejandro Herrera Trujillo https://orcid.org/0000-0002-9775-9405

Lina Vanessa Becerra Hernández https://orcid.org/0000-0002-4468-6716

##plugins.themes.bootstrap3.article.details##

Resumen

Teniendo en cuenta la alta incidencia y prevalencia del Trauma Craneoencefálico (TCE) en nuestro medio y reconociendo la epilepsia como una de las secuelas más comunes posteriores al trauma, es importante conocer cuáles son los medicamentos que tienen alta efectividad clínica en la terapia profiláctica para la prevención de la misma. El objetivo de este artículo es realizar una revisión de tema de acuerdo a lo publicado en la literatura reciente. La búsqueda se realizó en las bases de datos Pubmed, Uptodate y Scielo. Los fármacos de elección para las crisis epilépticas postraumáticas son los anticonvulsivantes. Se revisaron datos sobre la efectividad profiláctica de otros grupos farmacológicos, sin resultados actuales que apoyen su uso en la clínica. Se concluyó que las crisis epilépticas son una de las complicaciones más frecuentes después de sufrir un TCE y la literatura reporta que la terapia profiláctica es útil para la prevención de crisis epilépticas tempranas pero no hay consenso sobre la diferencia en cuanto a la efectividad entre fármacos anticonvulsivantes. El Levetiracetam tiene evidencia a favor tanto por su efectividad como por su seguridad, por lo que debe estudiarse a profundidad, pues sería uno de los candidatos como fármaco antiepileptogénico.

Keywords

Traumatiscos craneoencéfalicos, Epilepsia postraumática, Crisis tempranas, Terapia farmacológica, mecanismos de acción, Profilaxis

References
1. Braga P. Epilepsia Post-Traumática. Revista Chilena de Epilepsia. 2018
2. Henao A, Puerta N, Arcilla L. Manejo prehospitalario del trauma craneoencefálico por accidente de tránsito en la ciudad de Medellín Universidad CES; 2008.
3. Agustin D, Pahnke P, Piñero G, Videtta W, Aguilera S. Cuidados Intensivos en el trauma craneoencefálico grave. Acncx.org. 2017
4. Maas AI, Stocchetti N, Bullock R. Moderate and severe traumatic brain injury in adults. Lancet Neurol 2008; 7: 728-41
5. Gennarelli TA. Mechanisms of brain injury. J Emerg Med. 1993;11 Suppl 1:5-11.
6. Klein P, Tyrlikova I. Prevention of epilepsy: Should we be avoiding clinical trials? Ncbi.nlm.nih.gov. 2018
7. Medina Marín A, Escobar M. Sistema glutamatérgico, primera parte: Sinaptología, homeostasis y muerte celular 2018
8. Bergles D E, Diamond J S, Jahr C E. Clearance of glutamate inside the synapse and beyond. Curr Opin Neurobiol 1999; 9:29-38.
9. Prast H, PhilippuA. Nitric oxide as a modulator of neuronal function. Prog in Neurob 2001;64:51-68.
10. Kiss J, Vizi S. Nitric oxide. A novel link between synaptic and nonsynaptyc transmission. Trends in Neurosc 2001; 4(4): 211-5.
11. Sasaki M, Dawson V, Dawson T. The no signallingin thebrain. In: ReithMEA, editor. Cerebral signal transduction. From first to fourth messengers. Totowa: Humana Press; 2000. p. 151-74.
12. Barger S, Basile A. Activation of microglia by secreted amyloid precursor protein evokes reléase of glutamate by cystine exchange and attenuates synaptic function. J Neurochem 2001; 76(3): 846-54.
13. Pitkänen A, Bolkvadze T. Head trauma and epilepsy; 2012.
14. Hunt RFI, Boychuk JA, Smith BN. Neural circuit mechanisms of post-traumatic epilepsy. Front Cell Neurosci 2013;7:89.
15. Dudek FE, Staley KJ. The time course and circuit mechanisms of acquired epileptogenesis; 2012.
16. Riascos D et al. Neurodegenerative diversity in human cortical contusion: histological analysis of tissue derived from decompressive craniectomy. - PubMed - NCBI 2018
17. Prince DA, Parada I, Graber K. Traumatic brain injury and posttraumatic epilepsy; 2012.
18. Liu G, Gu B, He X-P, Joshi RB,Wackerle HD, Rodriguiz RM, et al. Transient inhibition of TrkB kinase after status epilepticus prevents development of temporal lobe epilepsy. Neuron 2013;79:31-8.
19. McDaniel SS,Wong M. Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis. Neurosci Lett 2011;497:231-9.
20. Drexel M, Puhakka N, Kirchmair E, Hörtnagl H, Pitkänen A, Sperk G. Expression of GABA receptor subunits in the hippocampus and thalamus after experimental traumatic brain injury. Neuropharmacology 2015;88:122-33.
21. González M, Lopera W, Arango A. Manual de Terapéutica. 17th ed. Medellín: Corporación para investigaciones biológicas (CIB); 2016.
22. Lexicomp, INC. Phenytoin: Drug information. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. . https://www.uptodate.com
23. Lexicomp, INC. Valproate: Drug information. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. . https://www.uptodate.com (Accessed on July 07, 2018)
24. Lexicomp, INC. Carbamazepine: Drug information. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. . https://www.uptodate.com
25. Lexicomp, INC. Levetiracetam: Drug information. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. . https://www.uptodate.com
26. Surges, R., Volynski, K. E., & Walker, M. C. (2008). Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited. Therapeutic advances in neurological disorders, 1(1), 13-24.
27. Jedrzejczak J et al. An observational study of first-line valproate monotherapy in focal epilepsy. - PubMed - NCBI 2018
28. Khan NR, VanLandingham MA, Fierst TM, et al. Should levetiracetam or phenytoin be used for posttraumatic seizure prophylaxis? a systematic review of the literature and meta-analysis. Neurosurgery 2016; 79:775–782.
29. Jones KE, Puccio AM, Harshman KJ, Falcione B, Benedict N, Jankowitz BT, et al. Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury. Neurosurg Focus 2008;25(4):E3.
30. Bratton SL, Chestnut RM, Ghajar J, et al. Antiseizure prophylaxis. J Neurotrauma 2007;24:S-83-6.
31. Temkin NR, Dikmen SS, Wilensky AJ, et al. A randomized, doubleblind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med 1990;323:497-502.
32. Kruer R, Harris L, Goodwin H, Kornbluth J, Thomas K, Slater L et al. Changing trends in the use of seizure prophylaxis after traumatic brain injury: A shift from phenytoin to levetiracetam
33. Zimmermann LL e. Treatment options for posttraumatic epilepsy. - PubMed - NCBI 2018
34. Wilson C, Burks J, Rodgers R, Evans R, Bakare A, Safavi-Abbasi S. Early and Late Posttraumatic Epilepsy in the Setting of Traumatic Brain Injury: A Meta-analysis and Review of Antiepileptic Management Author links open overlay panel 2018
35. Carney N, Totten AM, O’Reilly C, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. Neurosurgery 2017; 80:6–15. The most recently updated guidelines published by the brain trauma foundation on the management of severe TBI, September 2016
36. Yan HD, Ji-qun C, Ishihara K, et al. Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER). Epilepsia 2005;46:1170–1177.
37. Mazarati AM, Baldwin RA, Klitgaard H, et al. Treatment with levetiracetam during the latent period after experimental status epilepticus reduces chronic spontaneous recurrent seizures. Epilepsia 2003;44(Suppl. 9):223.
38. Sugaya Y, Maru E, Kudo K, et al. Levetiracetam suppresses development of spontaneous EEG seizures and aberrant neurogenesis following kainate-induced status epilepticus. Brain Res 2010;1352:187–199.
39. Kaminski RM, Rogawski MA, Klitgaard H. The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments. Neurotherapeutics 2014;11:385–400.
40. Zou H, Brayer SW, HurwitzM, Niyonkuru C, Fowler LE,Wagner AK. Neuroprotective, neuroplastic, and neurobehavioral effects of daily treatment with levetiracetam in experimental traumatic brain injury. Neurorehabil Neural Repair 2013;27:878-88.
41. Shetty AK. Prospects of levetiracetam as a neuroprotective drug against status epilepticus, traumatic brain injury, and stroke. Front Neurol 2013, 4 Nov:1–6.
42. Willmore LJ. Post-traumatic epilepsy: cellular mechanisms and implications for treatment. Epilepsia 1990;31(Suppl. 3):S67–73.
43. Gusakov I V, Ivanenko AI, Grantyn VA, Laur OI. Neurophysiologic and histopathologic correlates of the effect of deferoxamine on the formation of an epileptic focus during blood injection into the rat cerebral cortex. Patol Fiziol Eksp Ter n.d.:4–6.
44. Danbolt NC. Glutamate uptake. Prog in Neurob 2001; 65: 1-105
45. Mishra M, Singh R, Mukherjee S, Sharma D. Dehydroepiandrosterone's antiepileptic action in FeCl3-induced epileptogenesis involves upregulation of glutamate transporters. Epilepsy Res 2013;106:83–91.
46. Goodrich GS, Kabakov AY, Hameed MQ, Dhamne SC, Rosenberg PA, Rotenberg A. Ceftriaxone treatment after traumatic brain injury restores expression of the glutamate transporter, GLT-1, reduces regional gliosis, and reduces post-traumatic seizures in the rat. J Neurotrauma 2013;30:1434-41.
47. Jung KH, Chu K, Lee ST, Kim J, Sinn DI, Kim JM, et al. Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Neurobiol Dis 2006;23:237-46.
48. Bar-Klein G, Cacheaux LP, Kamintsky L, Prager O, Weissberg I, Schoknecht K, et al. Losartan prevents acquired epilepsy via TGF-β signaling suppression. Ann Neurol 2014;75:864-75.
49. Gao F, Liu Y, Li X, Wang Y, Wei D, Jiang W. Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model. Pharmacol Biochem Behav 2012;103:187-96.
50. Chu K, Jung KH, Lee ST, Kim JH, Kang KM, Kim HK, et al. Erythropoietin reduces epileptogenic processes following status epilepticus. Epilepsia 2008;49:1723-32.
51. Jung KH, Chu K, Lee ST, Park K Il, KimJH, Kang KM, et al. Molecular alterations underlying epileptogenesis after prolonged febrile seizure and modulation by erythropoietin. Epilepsia 2011;52:541-50.
52. Sandsmark DK, Pelletier C, Weber JD, Gutmann DH. Mammalian target of rapamycin: master regulator of cell growth in the nervous system. Histol Histopathol 2007;22:895–903.
53. Guo D, Zeng L, Brody DL,Wong M. Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury. PLoS One 2013;8.
54. Pitkänen A, Nehlig A, Brooks-Kayal AR, Dudek FE, Friedman D, Galanopoulou AS, et al. Issues related to development of antiepileptogenic therapies. Epilepsia 2013; 54(Suppl. 4):35–43.
55. White HS, Löscher W. Searching for the ideal antiepileptogenic agent in experimental models: single treatment versus combinatorial treatment strategies. Neurotherapeutics 2014;11:373-84.
56. Löscher W. Single versus combinatorial therapies in status epilepticus: novel data from preclinical models. Epilepsy Behav 2015;49:20-5.
Cómo citar
Siuffi Campo, S., Jiménez Cardozo, N., Herrera Trujillo, A., & Becerra Hernández, L. V. (2020). Profilaxis farmacológica de crisis epilépticas postraumáticas tempranas. Universitas Medica, 61(4). https://doi.org/10.11144/Javeriana.umed61-4.prof
Sección
Artículos de revisión